| A new evolutionary scenario for the Mycobacterium tuberculosis complex R Brosch, SV Gordon, M Marmiesse, P Brodin, C Buchrieser, K Eiglmeier, ... Proceedings of the national academy of Sciences 99 (6), 3684-3689, 2002 | 2147 | 2002 |
| A new evolutionary scenario for the Mycobacterium tuberculosis complex R Brosch, SV Gordon, M Marmiesse, P Brodin, C Buchrieser, K Eiglmeier, ... Proceedings of the national academy of Sciences 99 (6), 3684-3689, 2002 | 2147 | 2002 |
| The diarylquinoline TMC207 for multidrug-resistant tuberculosis AH Diacon, A Pym, M Grobusch, R Patientia, R Rustomjee, L Page-Shipp, ... New England Journal of Medicine 360 (23), 2397-2405, 2009 | 937 | 2009 |
| Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti AS Pym, P Brodin, R Brosch, M Huerre, ST Cole Molecular microbiology 46 (3), 709-717, 2002 | 876 | 2002 |
| Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis AS Pym, P Brodin, L Majlessi, R Brosch, C Demangel, A Williams, ... Nature medicine 9 (5), 533-539, 2003 | 789 | 2003 |
| Multidrug-resistant tuberculosis and culture conversion with bedaquiline AH Diacon, A Pym, MP Grobusch, JM de los Rios, E Gotuzzo, I Vasilyeva, ... New England Journal of Medicine 371 (8), 723-732, 2014 | 689 | 2014 |
| Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis NAJ Gillespie SH1, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR ... New England Journal of Medicine 371 (17), 1577-87, 2014 | 600 | 2014 |
| Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial G Theron, L Zijenah, D Chanda, P Clowes, A Rachow, M Lesosky, W Bara, ... The Lancet 383 (9915), 424-435, 2014 | 473 | 2014 |
| Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug … AH Diacon, PR Donald, A Pym, M Grobusch, RF Patientia, R Mahanyele, ... Antimicrobial agents and chemotherapy 56 (6), 3271-3276, 2012 | 426 | 2012 |
| Effect of katG Mutations on the Virulence of Mycobacterium tuberculosis and the Implication for Transmission in Humans AS Pym, B Saint-Joanis, ST Cole Infection and immunity 70 (9), 4955-4960, 2002 | 344 | 2002 |
| Genomic Deletions Classify the Beijing/W Strains as a Distinct Genetic Lineage of Mycobacterium tuberculosis AG Tsolaki, S Gagneux, AS Pym, YOL Goguet de la Salmoniere, ... Journal of clinical microbiology 43 (7), 3185-3191, 2005 | 307 | 2005 |
| The evolution of mycobacterial pathogenicity: clues from comparative genomics R Brosch, AS Pym, SV Gordon, ST Cole Trends in microbiology 9 (9), 452-458, 2001 | 294 | 2001 |
| Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis AS Pym, AH Diacon, SJ Tang, F Conradie, M Danilovits, C Chuchottaworn, ... European Respiratory Journal 47 (2), 564-574, 2016 | 290 | 2016 |
| Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis S Gagneux, MV Burgos, K DeRiemer, A Enciso, S Muņoz, PC Hopewell, ... PLoS pathogens 2 (6), e61, 2006 | 280 | 2006 |
| Systematic genetic nomenclature for type VII secretion systems W Bitter, ENG Houben, D Bottai, P Brodin, EJ Brown, JS Cox, ... PLoS pathogens 5 (10), e1000507, 2009 | 267 | 2009 |
| Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label … R Dawson, AH Diacon, D Everitt, C van Niekerk, PR Donald, DA Burger, ... The Lancet 385 (9979), 1738-1747, 2015 | 250 | 2015 |
| Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates … KA Cohen, T Abeel, A Manson McGuire, CA Desjardins, V Munsamy, ... PLoS medicine 12 (9), e1001880, 2015 | 230 | 2015 |
| Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing CRyPTIC Consortium and the 100,000 Genomes Project New England Journal of Medicine 379 (15), 1403-1415, 2018 | 212 | 2018 |
| Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance AL Manson, KA Cohen, T Abeel, CA Desjardins, DT Armstrong, CE Barry, ... Nature genetics 49 (3), 395-402, 2017 | 204 | 2017 |
| Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study JM Bryant, SR Harris, J Parkhill, R Dawson, AH Diacon, P van Helden, ... The Lancet Respiratory Medicine 1 (10), 786-792, 2013 | 195 | 2013 |
